The impact of fluoxetine on obesity and diabetes-related biomarkers in overweight and obese individuals: a systematic review and meta-analysis of randomized controlled trials.

BMC Psychiatry · 2025 · PMC12519731 · PMID 41083947

Europe PMC DOI

hedged sentences

0.0440

closest p · 0.9× alpha

0.0460

boldest claim

The sentences

borderline significantp = 0.044actually significant

4 , data from 8 RCT arms involving 607 participants (fluoxetine: 296; placebo: 311) showed a borderline significant decrease in HbA1c levels following fluoxetine treatment (WMD: − 0.61%; 95% CI: − 1.22 to − 0.016; p = 0.044), with significant between-study heterogeneity (I2 = 88%, p = 0.000).

also in 11,409 other papers

marginally significantp = 0.046actually significant

While fluoxetine yielded a modest reduction in FBS, the effect was marginally significant (WMD: − 8.70 mg/dL; 95% CI: − 17.25 to − 0.14; p = 0.046), with substantial heterogeneity observed (I2 = 92%, p < 0.001).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.